

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

RECEIVED
DEC 28 2000
File Information Unit

In re Application of

EDWARD TOBICIL

Application Number

09/256,388

Filed

5-23-99

Group Art Unit

Examiner

Paper No. #7

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE):

___ (A) referred to in United States Patent Number 6,055,557, column _____,

___ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____.

___ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or

___ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:



Signature

CHRIS PROFFITT

Typed or printed name

12-28-00

Date

FOR PTO USE ONLY

Approved by: 

(initials)

Unit: F: I: U



US006015557A

United States Patent [19]**Tobinick et al.**[11] **Patent Number:** **6,015,557**[45] **Date of Patent:** **Jan. 18, 2000**[54] **TUMOR NECROSIS FACTOR ANTAGONISTS
FOR THE TREATMENT OF
NEUROLOGICAL DISORDERS**5,656,272 8/1997 Le et al. .
5,795,967 8/1998 Aggarwal et al. .[76] **Inventors:** **Edward L. Tobinick; Arthur Jerome
Tobinick**, both of 100 UCLA Medical
Plz., Suite 205, Los Angeles, Calif.
90024-6903*Primary Examiner*—William R. A. Jarvis
Attorney, Agent, or Firm—Ezra Sutton[21] **Appl. No.:** **09/275,070**[22] **Filed:** **Mar. 23, 1999****Related U.S. Application Data**[63] Continuation-in-part of application No. 09/256,388, Feb. 24,
1999, abandoned.[51] **Int. Cl.⁷** **A61K 39/395; A61K 31/495;**
A61K 31/50; A61K 31/42[52] **U.S. Cl.** **424/134.1; 514/249; 514/378**[58] **Field of Search** **424/134.1; 514/249,**
514/378[56] **References Cited****U.S. PATENT DOCUMENTS**

5,605,690 2/1997 Jacobs et al. .

[57] **ABSTRACT**

A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing damage to neuronal tissue or for modulating the immune response affecting neuronal tissue of the human. The TNF antagonist administered is selected from the group consisting of etanercept and infliximab. The TNF antagonist is administered subcutaneously, intravenously, intrathecally, or intramuscularly.

Methotrexate or Leflunomide may be administered concurrently with the TNF antagonist for demyelinating diseases and certain other neurological disorders.

47 Claims, No Drawings